Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition downregulate epithelial markers and upregulate mesenchymal markers, introducing heterogeneity that complicates reliable identification of CTCs. In this study, we rationally designed a rose petal-derived micro-structured microchip featuring in situ grown ZnO nanorods, simultaneously functionalized with THP-1 cell membrane vesicles (TMVs) and multivalent aptamers, denoted as Mix-TMVs-RPD-ZnO-Chip. The replicated micro-structure establishes a dimensionally matched confinement that enhances contact area between CTCs and the functionalized surface. The TMVs effectively reduce non-specific adsorption of leukocyte cells. In parallel, the SYL3C and SJ3C2 aptamers balance binding thermodynamics and kinetics for epithelial CTCs (E-CTCs), while the NC3S aptamer enables capture of mesenchymal CTCs (M-CTCs). This design exhibits high-affinity towards E-CTCs and M-CTCs with dissociation constants of 6.125 nM and 22.46 nM, respectively, achieving capture efficiencies exceeding 90.8% and 87.1% within 45 min. The Mix-TMVs-RPD-ZnO-Chip also allows downstream analysis after release with high cell viability. Varying numbers of CTCs are successfully captured from blood samples of 48 patients with lung, colorectal, and breast cancer. Single-cell sequencing further confirms KRAS and p53 gene mutations in the captured CTCs. Overall, this approach holds potential for clinical trials in CTCs capture and analysis, promising disease diagnosis and guidance in clinical treatment.